ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Eurofarma Laboratorios, Takeda and Teva Pharmaceutical Industries side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Eurofarma LaboratoriosTakedaTeva Pharmaceutical Industries
studies on the registry651,754671
open to participants now7866
phase 3 studies under way6442
reach primary completion within a year1473
programswith a study of their own in two years6254

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseEurofarma LaboratoriosTakedaTeva Pharmaceutical Industries
Phase 100%

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%
00%
Phase 200%

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%

Teva Pharmaceutical Industries: 1 of its 4 programs at phase 2

  1. emrusolminphase 2
25%
Phase 3

Eurofarma Laboratorios: 6 of its 6 programs at phase 3

  1. Cyproterone Acetatephase 3
  2. Minoxidilphase 3
  3. N1087phase 3
  4. 2,4-thiazolidinedionephase 3
  5. N0750phase 3

and 1 more — sign in to see them all

100%

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%

Teva Pharmaceutical Industries: 2 of its 4 programs at phase 3

  1. TEV-53408phase 3
  2. tapinarofphase 3
50%
Approved, new studies00%

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Teva Pharmaceutical Industries: 1 of its 4 programs at approved, new studies

  1. deutetrabenazineapproved, new study
25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Eurofarma Laboratorios1 readouts · 1 phase 3···

Eurofarma Laboratorios, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Cyproterone Acetatephase 3 · Feb 0 · NCT06905210
········
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
Teva Pharmaceutical Industries1 readouts · 0 phase 3··

Teva Pharmaceutical Industries, Jan ’27: 1 program whose next study reaches primary completion

  1. emrusolminphase 2 · Jan 15 · NCT07674940
·········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Eurofarma Laboratorios

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Teva Pharmaceutical Industries

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionEurofarma LaboratoriosTakedaTeva Pharmaceutical Industries
Psoriasis2 of 3 · compare here–

Takeda in Psoriasis: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Psoriasis in search

Teva Pharmaceutical Industries in Psoriasis: 1 program

  1. tapinarofphase 3

Their studies: Teva Pharmaceutical Industries’ studies of Psoriasis in search

Vitiligo2 of 3 · compare here–

Takeda in Vitiligo: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Vitiligo in search

Teva Pharmaceutical Industries in Vitiligo: 1 program

  1. TEV-53408phase 3

Their studies: Teva Pharmaceutical Industries’ studies of Vitiligo in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Eurofarma Laboratorios 2 of 6 · Takeda 12 of 25 · Teva Pharmaceutical Industries 2 of 4 programs (16 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.